Objective To analyze the effects of albumin-bound paclitaxel therapy on tumor marker levels, serological indexes and toxic side effects in patients with advanced Triple negative breast cancer (TNBC). Methods A total of 103 female patients with advanced TNBC in our department from April 2020 to December 2022 were selected as study subjects and divided into control group (n=51) and observation group (n=52) according to random number table method. 51 cases in the control group were treated with capecitabine + vinorelbine. 52 patients in the observation group were treated with capecitabine + albumin-bound paclitaxel. The clinical efficacy, tumor marker level, serological index, survival rate (18 months follow-up) and toxicity of the two groups were compared. Results The disease control rate (DCR), objective response rate (ORR) and survival rate in observation group were higher than those in control group (P < 0.05). After treatment, the levels of CA153, CA125 and CEA tumor markers in both groups were decreased, and the observation group was lower than the control group (P < 0.05). TNF-α, CRP and IL-6 clear inflammatory factors were decreased in both groups after treatment, and the observation group was lower than the control group (P < 0.05). There was no statistical significance in the incidence of drug toxicity and side effects between two groups (P > 0.05). Conclusion Albumin-bound paclitaxel therapy can improve the overall clinical efficacy and survival rate of patients with advanced TNBC, improve the level of tumor markers and serological indicators, and have a good safety.